SOUTH PLAINFIELD, N.J.,
Oct. 19, 2016 /PRNewswire/
-- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that
the Company will host a webcast conference call to report its third
quarter financial results and provide an update on the company's
business and outlook on Wednesday, November
2, 2016 at 4:45 p.m. (ET)
after the closing of the market.
The call can be accessed by dialing (877) 303-9216 (domestic) or
(973) 935-8152 (international) five minutes prior to the start of
the call and providing the passcode 3969239. A live, listen-only
webcast of the conference call can be accessed on the investor
relations section of the PTC website at www.ptcbio.com. A webcast
replay of the call will be available approximately two hours after
completion of the call and will be archived on the company's
website for two weeks.
About PTC Therapeutics, Inc.
PTC is a global
biopharmaceutical company focused on the discovery, development and
commercialization of orally administered, proprietary small
molecule drugs targeting an area of RNA biology we refer to as
post-transcriptional control. Post-transcriptional control
processes are the regulatory events that occur in cells during and
after a messenger RNA is copied from DNA through the transcription
process. PTC's internally discovered pipeline addresses multiple
therapeutic areas, including rare disorders and oncology. PTC has
discovered all of its compounds currently under development using
its proprietary technologies. PTC plans to continue to develop
these compounds both on its own and through selective collaboration
arrangements with leading pharmaceutical and biotechnology
companies. For more information on the company, please visit our
website www.ptcbio.com.
For More Information Please Contact:
|
Media:
|
Investors:
|
Jane Baj
|
Emily
Hill
|
+1 (908)
912-9167
|
+ 1 (908)
912-9327
|
jbaj@ptcbio.com
|
ehill@ptcbio.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-third-quarter-financial-results-300347848.html
SOURCE PTC Therapeutics, Inc.